Donna Bowers
Medical · Tuttle, OKNPI 1750439394
Payments from drug & device makers
Across 1,056 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$961
- plus $6K from 24 others
What the payments were for
- Consulting fees$1151%
- Speaking & faculty fees$6344%
- Food & beverage$15,55694%
- Education$1941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 143 | $2,563 |
| AbbVie | 212 | $2,455 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 129 | $1,906 |
| Johnson & Johnson(2 entities) | 88 | $1,334 |
| Lundbeck LLC | 62 | $1,160 |
| Otsuka America Pharmaceutical, Inc. | 63 | $961 |
| Neurocrine Biosciences, Inc. | 73 | $849 |
| Alkermes, Inc. | 39 | $833 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $817 |
| Progenics Pharmaceuticals, Inc. | 3 | $634 |
| Almatica Pharma LLC | 34 | $570 |
| Vanda Pharmaceuticals Inc. | 32 | $434 |
| Axsome Therapeutics, Inc. | 15 | $310 |
| Supernus Pharmaceuticals, Inc. | 11 | $272 |
| Sunovion Pharmaceuticals Inc. | 45 | $226 |
| Idorsia Pharmaceuticals US Inc | 11 | $208 |
| Avanir Pharmaceuticals, Inc. | 10 | $171 |
| Novartis | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Astellas Pharma US Inc | 2 | $114 |
| Eisai Inc. | 6 | $109 |
| Indivior Inc. | 4 | $65 |
| Merck | 4 | $62 |
| Sage Therapeutics, LLC | 3 | $55 |
| Hollister Incorporated | 1 | $32 |
| Corium, LLC | 2 | $32 |
| Tonix Medicines, Inc. | 2 | $32 |
| Noven Therapeutics, LLC | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$634
- VRAYLAR$360
- AUSTEDO$225
- PLUVICTO$121
- INVEGA SUSTENNA$117
- SPRAVATO$115
- Austedo XR$111
- CAPLYTA$108
How this compares
$16,499 in reported general payments places this provider in the 95th percentile of 370 medical providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 28 | $255,164 |
| Austedo XrDeutetrabenazine | 30 | $194,283 |
| IngrezzaValbenazine Tosylate | 18 | $141,069 |
| VraylarCariprazine Hcl | 81 | $125,029 |
| SpravatoEsketamine Hcl | 24 | $43,805 |
| CaplytaLumateperone Tosylate | 17 | $34,429 |
| RexultiBrexpiprazole | 14 | $34,146 |
| Invega SustennaPaliperidone Palmitate | 12 | $22,174 |
| TrintellixVortioxetine Hydrobromide | 13 | $7,100 |
| Duloxetine Hcl | 225 | $4,386 |
| Aripiprazole | 101 | $4,200 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 100 | $3,753 |
| Bupropion XlBupropion Hcl | 135 | $3,017 |
| Clorazepate Dipotassium | 20 | $2,943 |
| Lamotrigine | 213 | $2,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,563 | $449,44758 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $849 | $141,06918 claims |
| AbbVieVraylar | $2,455 | $125,02981 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $1,334 | $65,97936 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,906 | $34,42917 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $961 | $34,14614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $817 | $7,10013 claims |
| Almatica Pharma LLCSertraline Hcl | $570 | $1,423117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 medical providers in Oklahoma.
Other medical in Tuttle
- Mebin ThomasOklahoma City$323K
- Kelle ChristiansonMidwest City$117K
- Kristine MurrowOklahoma City$81K
- Matthew DohlmanTulsa$39K
- Katelyn PuryearOklahoma City$22K
- Tara LinvilleTulsa$19K
- Debra OdomTulsa$17K
- Kelly WalworthOklahoma City$15K
- Jere ClaunchOklahoma City$15K
- Scott CooperArdmore$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.